Business Context and Reporting Period
This Form 8-K Current Report was filed by IRADIMED CORPORATION on February 11, 2021, regarding events occurring on February 8, 2021. The company is incorporated in Delaware and its common stock trades on the NASDAQ Capital Market under the symbol IRMD.
Key Financial Metrics
This filing is a current report regarding a material definitive agreement termination and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The primary material change reported is the termination of a material definitive agreement:
- Executive Termination: MaryBeth Smith, Vice President of Sales and Marketing, was terminated effective immediately on February 8, 2021.
- Reason for Termination: The Company concluded that Ms. Smith was actively engaged in outside business activities that conflicted with her duties without Company consent, violating Section 5 of her Employment Agreement dated January 3, 2020.
- Interim Leadership: Roger Susi, President and Chief Executive Officer, will assume the responsibilities of the Vice President of Sales and Marketing until a replacement is appointed.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, outlook, or management commentary on future performance. The primary risk disclosed is the operational impact of the sudden departure of a senior executive responsible for sales and marketing, though the CEO has assumed these duties temporarily.
Investor Verification Checklist
- Verify the timeline for the recruitment and appointment of a new Vice President of Sales and Marketing.
- Review the specific terms of the Employment Agreement (Exhibit 10.1 to the January 7, 2020, 8-K) to understand potential severance or legal implications.
- Monitor upcoming quarterly reports for any impact on sales performance or market share resulting from the leadership change.